Literature DB >> 22994458

A randomized controlled trial of a comprehensive migraine intervention prior to discharge from an emergency department.

Benjamin W Friedman1, Clemencia Solorzano, Jennifer Norton, Victoria Adewumni, Caron M Campbell, David Esses, Polly E Bijur, Seymour Solomon, Richard B Lipton, E John Gallagher.   

Abstract

OBJECTIVES: Patients who use an emergency department (ED) for acute migraine headaches have higher migraine disability scores, lower socioeconomic status, and are unlikely to have used a migraine-specific medication prior to presentation to the ED. The objective was to determine if a comprehensive migraine intervention, delivered just prior to ED discharge, could improve migraine impact scores 1 month after the ED visit.
METHODS: This was a randomized controlled trial of a comprehensive migraine intervention versus typical care among patients who presented to an ED for management of acute migraine. At the time of discharge, for patients randomized to comprehensive care, the research team reinforced their diagnosis, shared a migraine education presentation from the National Library of Medicine, provided them with six tablets of sumatriptan 100 mg and 14 tablets of naproxen 500 mg, and if they wished, provided them with an expedited free appointment to the institution's headache clinic. Patients randomized to typical care received the care their attending emergency physicians (EPs) felt was appropriate. The primary outcome was a between-group comparison of the Headache Impact Test (HIT-6) score, a validated headache assessment instrument, 1 month after ED discharge. Secondary outcomes included an assessment of satisfaction with headache care and use of migraine-specific medication within that 1-month period.
RESULTS: Over a 19-month period, 50 migraine patients were enrolled. One-month follow-up was successfully obtained in 92% of patients. Baseline characteristics were comparable. One-month HIT-6 scores in the two groups were nearly identical (59 vs. 56, 95% confidence interval [CI] for difference of 3 = -5 to 11), as was dissatisfaction with overall headache care (17% vs. 18%, 95% CI for difference of 1% = -22% to 24%). Patients randomized to the comprehensive intervention were more likely to be using triptans or migraine-specific therapy (43% vs. 0%, 95% CI for difference of 43% = 20 to 63%) 1 month later.
CONCLUSIONS: A comprehensive migraine intervention, when compared to typical care, did not improve HIT-6 scores (a validated measure of the effect of migraine on one's daily life) 1 month after ED discharge. Future work is needed to define a migraine intervention that is practical and useful in an ED, where many underserved patients, of necessity, present for care.
© 2012 by the Society for Academic Emergency Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22994458      PMCID: PMC3473153          DOI: 10.1111/j.1553-2712.2012.01458.x

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  16 in total

1.  How useful is the HIT-6 for measuring headache-related disability?

Authors:  Richard B Lipton
Journal:  Nat Clin Pract Neurol       Date:  2006-02

2.  Headache in the emergency department.

Authors:  Randolph W Evans; Benjamin W Friedman
Journal:  Headache       Date:  2011-08-16       Impact factor: 5.887

3.  The impact of intensive patient education on clinical outcome in a clinic-based migraine population.

Authors:  John Farr Rothrock; Victoria A Parada; Cheryl Sims; Kristin Key; Naomi S Walters; Richard M Zweifler
Journal:  Headache       Date:  2006-05       Impact factor: 5.887

4.  Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.

Authors:  J H Lofland; N E Johnson; A S Batenhorst; D B Nash
Journal:  Arch Intern Med       Date:  1999-04-26

5.  Burden of migraine in the United States: disability and economic costs.

Authors:  X H Hu; L E Markson; R B Lipton; W F Stewart; M L Berger
Journal:  Arch Intern Med       Date:  1999-04-26

6.  Migraine diagnosis and treatment: results from the American Migraine Study II.

Authors:  R B Lipton; S Diamond; M Reed; M L Diamond; W F Stewart
Journal:  Headache       Date:  2001 Jul-Aug       Impact factor: 5.887

7.  Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials.

Authors:  Ian Colman; Michael D Brown; Grant D Innes; Eric Grafstein; Ted E Roberts; Brian H Rowe
Journal:  BMJ       Date:  2004-11-18

8.  Use of the headache impact test (HIT-6) in general practice: relationship with quality of life and severity.

Authors:  F Nachit-Ouinekh; J-F Dartigues; P Henry; J-P Becg; G Chastan; N Lemaire; A El Hasnaoui
Journal:  Eur J Neurol       Date:  2005-03       Impact factor: 6.089

9.  An evaluation of the role of the ED in the management of migraine headaches.

Authors:  J A Salomone; R W Thomas; J R Althoff; W A Watson
Journal:  Am J Emerg Med       Date:  1994-03       Impact factor: 2.469

10.  Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test.

Authors:  Remy R Coeytaux; Jay S Kaufman; Ryon Chao; J Douglas Mann; Robert F Devellis
Journal:  J Clin Epidemiol       Date:  2006-04       Impact factor: 6.437

View more
  2 in total

1.  Introduction of a smartphone based behavioral intervention for migraine in the emergency department.

Authors:  Mia T Minen; Benjamin W Friedman; Samrachana Adhikari; Sarah Corner; Scott W Powers; Elizabeth K Seng; Corita Grudzen; Richard B Lipton
Journal:  Gen Hosp Psychiatry       Date:  2021-01-08       Impact factor: 3.238

Review 2.  A Framework for Estimating the Eligible Patient Population for New Migraine Acute Therapies in the United States.

Authors:  Linda Harris; Gilbert L'Italien; Thomas O'Connell; Zacharia Hasan; Susan Hutchinson; Sylvia Lucas
Journal:  Adv Ther       Date:  2021-05-31       Impact factor: 3.845

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.